본문 바로가기

The role of local ablative therapy in patients with advanced invasive mucinous adenocarcinoma of the lung

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q3
피인용
Web of Science 2Scopus 2
FWCI (Scopus)
0.23
JCR IF
JCR 2023 2.7
ISSN
0171-5216

저자

  1. 김수한제1저자Pusan Natl Univ, Sch Med, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea
  2. 성하영Pusan Natl Univ, Sch Med, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea
  3. 이종근Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Thorac & Cardiovasc Surg, Pusan, South Korea
  4. 안효영Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Thorac & Cardiovasc Surg, Pusan, South Korea
  5. 조정수Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Thorac & Cardiovasc Surg, Pusan, South Korea
  6. 이호석Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Thorac & Cardiovasc Surg, Pusan, South Korea
  7. 김영대Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Thorac & Cardiovasc Surg, Pusan, South Korea
  8. 이민기Pusan Natl Univ, Sch Med, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea
  9. 엄중섭Pusan Natl Univ, Sch Med, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea
  10. 김미현교신저자Pusan Natl Univ, Sch Med, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea

초록

Purpose: Invasive mucinous adenocarcinoma (IMA) of the lungs is a rare subtype of lung adenocarcinoma with a limited understanding of its prognosis, particularly in advanced stages. This study aimed to assess the prognosis of patients with advanced IMA by focusing on treatment modalities. Methods: This single-center retrospective study evaluated 33 patients with IMAs diagnosed with advanced-stage disease or disease progression after curative treatment between 2011 and 2021. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS). OS and PFS were calculated from the date of the diagnosis of advanced IMA. Results: The study cohort included 13 patients at the initial advanced stage and 20 patients who progressed after curative treatment. Treatment modalities included conventional chemotherapy in 24 patients (72.7%), targeted therapy in seven (21.2%), immunotherapy in 13 (39.4%), and local ablative therapy (LAT) in 13 (39.4%). The median OS was 32 months (95% confidence interval [CI], 2.9–61.0), with LAT significantly associated with improved OS compared to non-LAT treatment (not reached vs. 11.3 months, p = 0.001). However, there was no significant difference in OS based on conventional chemotherapy (p = 0.396), targeted therapy (p = 0.655), or immunotherapy (p = 0.992). In multivariate analysis, LAT remained an independent prognostic factor for OS (hazard ratio, 0.125; 95% CI, 0.026–0.608; p = 0.01). PFS was 8.6 months (95% CI, 3.6–13.7), with no significant differences observed among the treatment modalities. Conclusion: Our findings suggest that LAT may provide favorable survival outcomes in patients with advanced IMA.

키워드

AdenocarcinomaLocal ablative therapyLung neoplasmsMucinousPrognosisCANCERCLASSIFICATIONFEATURESIMPACT

식별자

Scopus EID
2-s2.0-85202996187
WoS UID
001306375800002